- Conditions
- Premature Ejaculation
- Interventions
- PSD502, contains a mixture of lidocaine and prilocaine, Placebo
- Drug
- Lead sponsor
- Plethora Solutions Ltd
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2329–2352
of 5,570
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Xenon129 MRI imaging, Gadolinium MRI, Advair (250mcg/50mcg) one puff twice a day
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
- Interventions
- XB002, Nivolumab, Bevacizumab
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more
- Conditions
- HIV Infections
- Interventions
- Zidovudine, Didanosine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Months to 18 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1995
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Metastatic Cancer, Melanoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer
- Interventions
- VE800, Nivolumab, Vancomycin Oral Capsule
- Biological · Drug
- Lead sponsor
- Vedanta Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 13 more
- Conditions
- Healthy
- Interventions
- MK-8527, FTC/TDF
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- HIV Infections
- Interventions
- ATV, Ritonavir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 91 Days to 21 Years
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2014
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Alhambra, California • La Jolla, California + 23 more
- Conditions
- Hepatitis C Virus Infection
- Interventions
- SOF/VEL/VOX, SOF/VEL
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 43
- States / cities
- Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more
- Conditions
- HIV Infections
- Interventions
- Lamivudine/Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years to 24 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2002
- U.S. locations
- 19
- States / cities
- Los Angeles, California • San Diego, California • Jacksonville, Florida + 13 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 186
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
- Conditions
- Metastatic Melanoma
- Interventions
- Bempegaldesleukin (NKTR-214), Nivolumab, ⁸⁹Zr-Df-IAB22M2C
- Biological · Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Duarte, California • Portland, Oregon • Philadelphia, Pennsylvania
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- U3-1287, Erlotinib, Placebo
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 14
- States / cities
- Glendale, Arizona • Scottsdale, Arizona • Anaheim, California + 11 more
- Conditions
- Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
- Interventions
- Buprenorphine Injection, Buprenorphine Sublingual Product
- Drug
- Lead sponsor
- T. John Winhusen, PhD
- Other
- Eligibility
- 18 Years to 41 Years · Female only
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 12
- States / cities
- Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more
- Conditions
- Solid Tumor
- Interventions
- Oraxol, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Athenex, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Detroit, Michigan + 1 more
- Conditions
- Platinum Resistant Ovarian Cancer
- Interventions
- losartan, Paclitaxel
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- alvocidib, vorinostat, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Candidiasis, HIV Infections
- Interventions
- Methadone hydrochloride, Fluconazole
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1994
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent)
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 17
- States / cities
- Oakland, California • Roseville, California • San Francisco, California + 13 more
- Conditions
- Breast Cancer
- Interventions
- MR-compatible scinti-mammography (MRI-SMM) system
- Device
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Cystic Fibrosis
- Interventions
- ELX/TEZ/IVA, IVA, TEZ/IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 32 more
- Conditions
- Prostate Cancer
- Interventions
- Cabazitaxel (XRP6258), Prednisone (or Prednisolone)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 21
- States / cities
- Muscle Shoals, Alabama • Hot Springs, Arkansas • Anaheim, California + 18 more
- Conditions
- HIV Infections
- Interventions
- Nelfinavir mesylate, Saquinavir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 6 Months to 13 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Nutley, New Jersey
- Conditions
- Human Papillomavirus-Negative Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma, Resectable Human Papillomavirus-Independent Head and Neck Mucosal Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma, Resectable Head and Neck Squamous-cell Carcinoma
- Interventions
- Biospecimen Collection, Chemotherapy, Decitabine, External Beam Radiation Therapy, Questionnaire Administration, Surgical Procedure
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Colorectal Cancer
- Interventions
- Axitinib, Bevacizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 12
- States / cities
- Jonesboro, Arkansas • Fort Myers, Florida • Pensacola, Florida + 9 more